|本期目录/Table of Contents|

[1]吴文清,柯传庆,江龙委,等.树突状细胞-细胞因子诱导的杀伤细胞联合放化疗在局部晚期非小细胞肺癌中的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2025,38(01):67-72.[doi:10.16571/j.cnki.2097-2768.2025.01.011]
　WU Wenqing,KE Chuanqing,JIANG Longwei,et al.Efficacy of DC-CIK combined with chemoradiotherapy in locally advanced non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2025,38(01):67-72.[doi:10.16571/j.cnki.2097-2768.2025.01.011]
点击复制

树突状细胞-细胞因子诱导的杀伤细胞联合放化疗在局部晚期非小细胞肺癌中的疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
38卷
期数:
2025年01期
页码:
67-72
栏目:
论著·临床研究
出版日期:
2025-01-20

文章信息/Info

Title:
Efficacy of DC-CIK combined with chemoradiotherapy in locally advanced non-small cell lung cancer
文章编号:
2097-2768（2025）01-0067-06
作者:
吴文清; 柯传庆; 江龙委; 吴嘉; 孙玲
作者单位：330000 南昌，中国人民解放军联勤保障部队第九○八医院肿瘤科（吴文清、柯传庆、吴嘉、孙玲）；210002 南京，东部战区总医院秦淮医疗区肿瘤科（江龙委）
Author(s):
WU Wenqing; KE Chuanqing; JIANG Longwei; WU Jia; SUN Ling
（1.Department of Oncology ，the 908th Hospital of the Joint Logistics Support Force ，PLA ，Nanchang 330000，Jiangxi，China；2.Department of Oncology，Qinhuai Medical Treatment Area，General Hospital of Eastern TheaterCommand，PLA，Nanjing 210002，Jiangsu，China）
关键词:
树突状细胞; 细胞因子诱导的杀伤细胞; 放疗; 化疗; 1; 25-二羟维生素D3
Keywords:
dendritic cells; cytokine-induced killer cells; radiotherapy; chemotherapy; 1; 25-dihydroxyvitamin D3
分类号:
R734.2
DOI:
10.16571/j.cnki.2097-2768.2025.01.011
文献标志码:
A
摘要:
目的 观察树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）联合放化疗治疗非小细胞肺癌的疗效。方法回顾性分析2020年10月至2021年9月东部战区总医院秦淮医疗区肿瘤科收治的局部晚期非小细胞肺癌患者60例，其中行DCCIK联合放化疗治疗的30例患者为联合组，同期接受单纯放化疗治疗的30例患者为对照组，统计患者的临床资料及治疗前后1，25-二羟维生素D3、T细胞亚群的变化，分析1，25-二羟维生素D3及T细胞亚群与治疗疗效的关系。结果治疗后联合组客观缓解率和疾病控制率均高于对照组（80% vs 76.7%、93.3% vs 90%），但差异无统计学意义（P>0.05）；联合组患者中位无疾病进展生存时间（PFS）、中位总生存期（OS）均高于对照组（14.6个月vs 9.3个月、25.8个月vs 18.5个月），差异均有统计学意义（P<0.05）；联合组患者治疗后CD3+、CD4+、CD8+、CD56+T细胞水平及CD4+/ CD8+比值均较治疗前升高，对照组治疗后上述细胞水平均下降，联合组治疗后的淋巴细胞水平均高于对照组，其中CD3+、CD4+、CD4+/ CD8+组间差异有统计学意义（P<0.05）；患者治疗前后1，25-二羟维生素D3变化及2组间差异无统计学意义（P>0.05）。2组治疗过程中无严重不良反应发生。结论DC-CIK联合放化疗治疗局部晚期非小细胞肺癌能提高患者PFS和OS，是安全有效的，能达到更好的临床获益并改善免疫功能。
Abstract:
Objective The efficacy of DC-CIK and chemoradiotherapy in non-small cell lung cancer was observed. MethodsA retrospective analysis of 60 patients with locally advancednon-small cell lung cancer admitted from October 2020 to September 2021，including 30 patients treated with chemotherapy combined with DC-CIK in the observation group，and 30 patients with radiotherapy com?bined with chemotherapy in the control group. The clinical data，the changes of 1，25-dihydroxyvitamin D3 and T cell subsets before andaftertreatment，andtherelationshipbetween 1，25-dihydroxyvitaminD3 andTcellsubsetsandtreatmentefficacywereanalyzed. ResultsThe objective response rates in the observed and control groups were 80% and 76.7%，respectively（P>0.05）. while the disease controlrates of 93.3% and 90%，respectively（P>0.05）. The median PFSand median OS in the observation group were higher than those inthe control group（14.6 months vs 9.3 months，25.8 months vs 18.5months，P<0.05）. In the observation group，CD3+ ，CD4+ ，CD8+ ，CD4+/ CD8+and CD56+ T cells levels increased after treatment com?pared to baseline levels. The above cell levels were all decreased af?ter treatment in the control group. The post-treatment lymphocytelevels in the observation group were higher than those in the controlgroup，with statistically significant differences observed in CD3+ ，CD4+ ，and CD4+/CD8+ levels（P<0.05）. No significant differences were found in 1，25-dihydroxyvitamin D3 levels before and after treatment between the two groups（P>0.05）. No serious adverse reac?tions occurred during the treatment process. Conclusion The combination of DC-CIK with radiotherapy and chemotherapy for locallyadvanced non-small cell lung cancer can improve PFS and OS，is safe and effective，and provide better clinical benefits and improvingimmune function.

参考文献/References:

［1］ 张兵喜.诱导化疗加同步放化疗与单纯同步放化疗治疗局部晚期非小细胞肺癌临床疗效比较［J］.中国药物与临床，2020，20（24）:4139-4141.［2］ 国家卫生健康委办公厅.原发性肺癌诊疗指南（2022年版）［J］.协和医学杂志，2022，13（4）:549-570.［3］ 黄培，孙清，赵帆，等.奈达铂同步放化疗治疗无手术指征食管癌的增敏疗效及临床观察［J］.现代肿瘤医学，2020，28（4）:595-598.［4］ 李艳，严胡铃，石瑛，等.肝细胞癌过继细胞免疫治疗研究进展［J］.临床肝胆病杂志，2020，36（8）:1852-1857.［5］ Ren PT，Zhang Y.Comparative investigation of the effects of spe?cific antigen-sensitized DC-CIK and DC-CTL cells against B16melanoma tumor cells［J］. Mol Med Rep，2017，15（4）: 1533-1538.［6］ Zhan HL，Gao X，Pu XY，et al.A randomized controlled trial ofpostoperative tumor lysate-pulsed dendritic cells and cytokineinducedkiller cells immunotherapy in patients with localizedand locally advanced renal cell carcinoma［J］.Chin Med J（Engl），2012，125（21）:3771-3777.［7］ DelPreteA，SalviV，SorianiA，et al.Dendriticcellsubsetsincancerimmunity and tumor antigen sensing［J］.Cell Mol Immunol，2023，20（5）:432-447.［8］ 马晓骉，罗峰，高永亮，等.ClK细胞免疫疗法联合化疗治疗非小细胞肺癌的临床疗效［J］.昆明医科大学学报，2020，41（12）:60-67. ［9］ Yuan X，Zhang AZ，Ren YL，et al.Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapyfor the treatment of esophageal cancer: A meta-analysis［J］.Medi?cine（Baltimore），2021，100（13）:e24519.［10］ 彭黎明，杨林.胃癌过继性T淋巴细胞免疫治疗的研究进展［J］.癌症进展，2020，18（9）:879-927，934.［11］ Sadeghzadeh M，Bornehdeli S，Mohahammadrezakhani H，et al.Dendritic cell therapy in cancer treatment；the state- of-the-art［J］.Life Sci，2020，254:117580.［12］ De Martino M，Daviaud C，Vanpouille-Box C.Radiotherapy: Animmune response modifier for immuno-oncology［J］.Semin Im?munol，2021，52:101474.［13］ Goedegebuure RSA，de Klerk LK，Bass AJ，et al.Combining Ra?diotherapy With Anti- angiogenic Therapy and Immunotherapy；A Therapeutic Triad for Cancer?［J］Front Immunol，2019，9:3107.［14］ 王康馨，赵阳，闫婧.肿瘤放疗联合免疫检查点阻断治疗的应用进展［J］.医学研究生学报，2019，32（6）:637-641.［15］ McLaughlin M，Patin EC，Pedersen M，et al.Inflammatory micro?environment remodelling by tumour cells after radiotherapy［J］.Nat Rev Cancer，2020，20（4）:203-217.［16］ 陈焕，徐裕金.免疫检查点抑制剂与放疗联合治疗局部晚期不可切除非小细胞肺癌的介入时机的研究进展［J］.中国肿瘤生物治疗杂志，2023，30（12）:1110-1115.［17］ 余绮雯.同步放化疗联合CIK治疗局部晚期鼻咽癌的十年随访结果：一项Ⅱ期临床试验［D］.广州：广东药科大学，2022.［18］ 李工，孔怡琳，詹文婷，等.三维适形/调强放疗结合化疗联合DC-CIK免疫治疗Ⅱ，Ⅲ期非小细胞肺癌疗效分析［J］.安徽医药，2015，19（7）:1358-1360.［19］ 陆坤，沈辉，陈茜，等.卡瑞利珠单抗联合放化疗对局部晚期非小细胞肺癌患者生存预后的影响［J］.医学研究与战创伤救治，2023，36（10）:1066-1071.［20］ Dovnik A，Dovnik NF.Vitamin D and Ovarian Cancer: Systemat?ic Review of the Literature with a Focus on Molecular Mecha?nisms［J］.Cells，2020，9（2）:335.［21］ 邱海山，屈莹莹，赖卫民.血清1，25-二羟维生素D3水平与肺癌的相关性分析［J］.解放军预防医学杂志，2019，37（4）:140-141.［22］ Li J，Xuan S，Dong P，Xiang Z，et al.Immunotherapy of hepatocel?lular carcinoma: recent progress and new strategy［J］.Front Im?munol，2023，14:1192506.［23］ Vaughan-Shaw PG，O?Sullivan F，Farrington SM，et al.The impactof vitamin D pathway genetic variation and circulating 25-hy?droxyvitamin D on cancer outcome: systematic review and metaanalysis［J］.Br J Cancer，2017，116（8）:1092-1110.

相似文献/References:

[1]孔练花,李 军,韩亚萍,等.基因修饰的树突状细胞体外免疫功能的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):481.
　KONG Lian-hua,LI Jun,HAN Ya-ping,et al.The preliminary study on the immune function of the gene modified dendritic cells in vitro[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(01):481.
[2]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(01):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[3]苏寒,毛钊,陈伟,等.牙龈卟啉单胞菌脂多糖对树突状细胞成熟及功能影响的体外研究[J].医学研究与战创伤救治(原医学研究生学报),2017,19(05):465.[doi:10.3969/j.issn.1672-271X.2017.05.005]
　SU Han,MAO Zhao,CHEN Wei,et al.Effects of Porphyromonas gingivalis-lipopoly saccharide on the maturation and functions of dendritic cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(01):465.[doi:10.3969/j.issn.1672-271X.2017.05.005]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2025-01-20